Vaccinations in Children and Adolescents Treated With Immune-Modifying Biologics: Update and Current Developments

• Published in: The journal of allergy and clinical immunology in practice (Cambridge, MA) Vol. 10; no. 6; p. 1485
• Main Authors: Martire, Baldassarre, Ottaviano, Giorgio, Sangerardi, Maria, Sgrulletti, Mayla, Chini, Loredana, Dellepiane, Rosa Maria, Montin, Davide, Rizzo, Caterina, Pignata, Claudio, Marseglia, Gian Luigi, Moschese, Viviana
• Format: Journal Article
• Language: English
• Published: United States 01.06.2022
• Subjects: Adolescent; Biological Products - therapeutic use; Child; Humans; Immunization; Quality of Life; Vaccination; Vaccines - therapeutic use; Biologics; Children; Vaccinations
• ISSN: 2213-2201
• DOI: 10.1016/j.jaip.2022.01.007

Treatment with immune-modifying biologics has positively impacted disease control and quality of life in many patients with immune-mediated disorders. However, the higher susceptibility to common and opportunistic pathogens is of concern. Thus, immunization strategies to control vaccine-preventable diseases represent a critical issue in this population. However, limited data exist on the safety, immunogenicity, and efficacy of available vaccines in patients on biologics, particularly in children. Here, according to published literature and real-life experience and practice, we report the interim indications of the Italian Society of Pediatric Allergology and Immunology (SIAIP) Vaccine Committee and of the Italian Primary Immunodeficiency Network (IPINet) Centers on immunization of children and adolescents receiving biologics. Our aim is to provide a practical guidance for the clinician to ensure optimal protection for patients and the community.